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ABSTRACT
Objective Variation in the fat mass and obesity-
associated (FTO) gene inﬂuences susceptibility to obesity.
A variant in the FTO gene has been implicated in genetic
risk to osteoarthritis (OA). We examined the role of the
FTO polymorphism rs8044769 in risk of knee and hip
OA in cases and controls incorporating body mass index
(BMI) information.
Methods 5409 knee OA patients, 4355 hip OA
patients and up to 5362 healthy controls from 7
independent cohorts from the UK and Australia were
genotyped for rs8044769. The association of the FTO
variant with OA was investigated in case/control analyses
with and without BMI adjustment and in analyses
matched for BMI category. A mendelian randomisation
approach was employed using the FTO variant as the
instrumental variable to evaluate the role of overweight
on OA.
Results In the meta-analysis of all overweight
(BMI≥25) samples versus normal-weight controls
irrespective of OA status the association of rs8044769
with overweight is highly signiﬁcant (OR[CIs] for allele
G=1.14 [01.08 to 1.19], p=7.5×10−7). A signiﬁcant
association with knee OA is present in the analysis
without BMI adjustment (OR[CIs]=1.08[1.02 to 1.14],
p=0.009) but the signal fully attenuates after BMI
adjustment (OR[CIs]=0.99[0.93 to 1.05], p=0.666). We
observe no evidence for association in the BMI-matched
meta-analyses. Using mendelian randomisation
approaches we conﬁrm the causal role of overweight
on OA.
Conclusions Our data highlight the contribution of
genetic risk to overweight in deﬁning risk to OA but the
association is exclusively mediated by the effect on BMI.
This is consistent with what is known of the biology of
the FTO gene and supports the causative role of high
BMI in OA.
INTRODUCTION
Osteoarthritis (OA) is the most common articular
disease in the developed world and a leading cause
of chronic disability, mostly as a consequence of
knee OA and/or hip OA.1 A number of studies have
shown that obesity represents one of the most
important risk factors and it is also a predictor for
progression of OA, especially of the knee joint and
less of the hip joint. There is a strong and highly
signiﬁcant relationship between body mass index
(BMI) and OA of the knee. The relationship with
hip OA is less striking but is still highly statistically
signiﬁcant2 3 and obesity is one of the strongest
prognostic factors for large joint OA.4
Genome-wide association studies (GWAS), which
test the correlation between single-nucleotide poly-
morphisms (SNPs) across the entire genome and
trait variation in a sample of individuals, have suc-
ceeded in identifying variants associated reprodu-
cibly with complex traits. The association between
FTO SNPs and BMI and the risk of being over-
weight or obese has been conﬁrmed in multiple
populations.5 The effect of FTO SNPs on BMI is
modest, with those individuals homozygous for the
risk allele weighing, on average, 3 kg more than
those homozygous for the protective allele.6
The protein encoded by FTO has been described
as a Fe(II)-oxoglutarate-dependent oxygenase and
2-oxoglutarate-dependent oxygenase that might
operate as a DNA demethylase. The human FTO
gene is expressed in many tissues including mesen-
teric fat, pancreas, liver and adipose tissue, with the
highest concentrations found in the hypothalamus.7
Experimental animal studies provide direct func-
tional evidence that FTO underlies obesity.8 Two
studies have demonstrated that FTO gene expres-
sion in the arcuate nucleus of the hypothalamus is
regulated by fasting,9 10 suggesting that FTO may
be important to the control of energy homeostasis.
A recent GWAS on hip and/or knee OA has identi-
ﬁed a variant in the FTO gene, rs8044769, as being
strongly associated with risk of OA.11 Because of the
study design, the authors were not able to test thor-
oughly whether the association between FTO and
OA was mediated by obesity or not. GWAS for type
2 diabetes (T2D) detected strong association
between common SNPs in the FTO region and risk
of T2D.6 12 13 However, subsequent analyses
showed that the association between FTO SNPs and
T2D was mediated by an association with BMI.6
There has been a lot of debate in the literature
recently about the role of FTO in OA pathogenesis
and speciﬁcally about the direction of causation
between obesity and OA.14 15 Mendelian random-
isation, a form of instrumental variable analysis, is a
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method of using measured variation in genes of known function
to examine the causal effect of a modiﬁable exposure on disease
in non-experimental studies.16 The main elements for it to work
(having removed the effect of confounders) are that the genetic
variant should be reliably associated with the exposure, in this
case overweight status, and that there should be no direct effect
of genotype on disease or any other mediated effect other than
through the exposure of interest. In our study we ﬁnd that these
conditions apply to the relationship between FTO, overweight
and OA.
The aim of the present study is to elucidate the role of
rs8044769 in genetic risk of OA by testing this SNP in seven
independent study cohorts from the UK and Australia with BMI
information comprising in total 5409 knee OA patients, 4355
hip OA patients and 5362 healthy individuals. We explore the
causality and direction of the relationship between overweight
status and OA using the FTO polymorphism as the instrumental
variable in a mendelian randomisation analysis.
PATIENTS AND METHODS
We examined genotypes for rs8044769 in knee or hip OA cases
and controls with BMI information coming from seven inde-
pendent studies (table 1 and see online supplementary methods).
These comprised: a subset of knee or hip OA cases from the
arcOGEN GWAS versus disease-free controls from TwinsUK, and
individuals from the Chingford Study, the Hertfordshire Cohort
Study (HCS), the Nottingham Case-Control Study, the Genetics
of Osteoarthritis and Lifestyle study, the TwinsUK study and the
Tasmanian Older Adult Cohort (TASOAC) study.2 11 17–22 Cases
had either radiographic evidence of the disease with a Kellgren–
Lawrence (KL) grade ≥2 or clinical evidence of the disease to a
level requiring total joint replacement. Controls were disease-free
individuals with KL<2. Individuals from the arcOGEN,
Chingford, TwinsUK and the Nottingham cohort with full
GWAS information have been subjected to standard GWAS
quality control including removal of ethnic outliers. The HCS
includes only individuals of self-reported Caucasian origin from
within the Hertfordshire county, and TASOAC individuals
included in this study are all of self-reported British origin and of
white ethnicity (see online supplementary methods). Ethical
approval for each study was obtained from the relevant ethical
committees and all participants gave written informed consent.
We carried out case/control logistic regression analyses for
rs8044769 under the multiplicative model (adjusting for gender
and BMI were applicable by including them in the model as
covariates) and combined summary statistics in a meta-analysis
framework (see online supplementary methods). To evaluate the
association of the FTO variant with risk of overweight/obese we
classiﬁed all overweight/obese samples as cases and normal
weight subjects as controls in each cohort (irrespective of OA
status). For the BMI-matched analyses, we stratiﬁed the OA hip
or knee cases and the controls into three categories for each
cohort according to BMI: normal weight ≤25, overweight and
obese >25 and obese only >30.
RESULTS
We analysed genotypes for rs8044769 across a total of 936
normal weight, 2092 overweight and 2381 obese knee OA
patients versus 2501 normal weight, 1984 overweight and 877
obese controls and of 1201 normal weight, 1758 overweight and
1396 obese hip OA patients versus 2315 normal weight, 1804
overweight and 848 obese healthy controls from seven independ-
ent cohorts from the UK and Australia (table 1). First, we investi-
gated the association of the FTO variant with risk of obesity in a
case/control analysis of all overweight/obese samples (n=10 538)
versus normal weight controls (n=4598) irrespective of OA
status and found that to be highly signiﬁcant. Allele G at
rs8044769 was associated with risk of overweight/obesity
(BMI≥25) with an OR[CIs]=1.14 [01.08 to 1.19], p=7.5×10−7
and no heterogeneity was observed between studies (heterogen-
eity index, I2=0). We then examined the strength of association
of rs8044769 with knee or hip OA across all OA cases versus
controls in each cohort (adjusted for gender) and repeated the
analyses adjusting for BMI. A signiﬁcant association of the FTO
variant with knee OA only was detected in the meta-analysis
without BMI adjustment (OR[CIs]=1.08[1.02 to 1.14],
p=0.009) (table 2). The effect of this variant on knee OA is
slightly larger and more signiﬁcant in the analysis of the two
genders combined but it appears to be mainly driven by females
(see online supplementary table S1) with OR in females=1.07
Table 1 Descriptive characteristics of the study cohorts
Study Country of origin
Cases Controls (OA unaffected)
OA status Definition N F (%)
BMI±SD
[kg/m2] Age±SD [yrs] Definition N F (%)
BMI±SD
[kg/m2] Age±SD [yrs]
arcOGEN UK Hip KL≥2 or THR 1310 100 28.4±5.8 64.7±9.1 KL<2 1671 100 25.3±4.8 56.8±13.8
arcOGEN UK Knee KL≥2 or TKR 1209 100 30.6±6.3 66.0±8.7 KL<2 1671 100 25.3±4.8 56.8±13.8
Chingford UK Hip KL≥2 or THR 97 100 25.0±3.9 66.0±5.6 KL<2 677 100 24.6±3.5 63.1±5.7
Chingford UK Knee KL≥2 or TKR 266 100 27.1±4.6 65.7±5.9 KL<2 556 100 24.6±3.5 63.1±5.7
GOAL UK Hip KL≥2 or THR 1291 48.7 29.4±5.13 67.8±7.2 KL<2 788 49.7 27.1±4.4 62.7±8.4
GOAL UK Knee KL≥2 or TKR 1619 47.0 30.7±5.4 68.5±7.1 KL<2 788 49.7 27.1±4.4 62.7±8.4
HSC UK Knee KL≥2 or TKR 148 40.1 29.4±5.1 65.2±2.6 KL<2 555 48.9 26.2±3.7 64.8±2.6
Nottingham UK Hip KL≥2 or THR 1525 63.2 27.7±4.7 68.5±9.2 KL<2 750 56.9 26.6±3.9 66.3±9.0
Nottingham UK Knee KL≥2 or TKR 1780 55.3 29.7±5.3 69.0±8,8 KL<2 750 56.9 26.6±3.9 66.3±9.0
TASOAC Australia Hip KL≥2 44 65.1 29.4±5.4 65.4±7.5 KL<2 696 50.4 27.4±4.5 62.3±7.4
TASOAC Australia Knee KL≥2 239 49.8 29.3±5.2 67.3±7.3 KL<2 657 46.0 27.4±4.5 62.3±7.4
TwinsUK UK Hip KL≥2 or THR 88 100 26.0±4.6 57.4±8.0 KL<2 385 100 24.3±4.1 50.3±6.7
TwinsUK UK Knee KL≥2 or TKR 148 100 28.1±5.3 58.8±7.5 KL<2 385 100 24.3±4.1 50.3±6.7
GOAL, Genetics of Osteoarthritis and Lifestyle; TASOAC, Tasmanian Older Adult Cohort.
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[1.00–1.15], p=0.049, I2=0.54 versus OR in males=1.04[0.94–
1.14], p=0.47, I2=0, which is in accordance with the ﬁnding
reported in the arcOGEN GWAS.11 After excluding 2323 knee
OA cases and 1671 controls that were part of the arcOGEN
GWAS discovery study11 we observe that the effect size is smaller
in the replication studies (OR[CIs]=1.04[0.97 to 1.12]) and not
signiﬁcant (p=0.24).
The association signal was fully attenuated after BMI adjustment
(table 2) (OR[CIs]=0.99[0.93 to 1.05], p=0.666) in accordance
with the ﬁnding reported in the full arcOGEN GWAS.11 Adjusting
for age as well as BMI did not make a noticeable difference in
these results (table 2). We further investigated the FTO association
by performing a large-scale meta-analysis across all case/control
datasets matched for BMI but observed no evidence for association
in any of the BMI strata studied (table 3). The power of our
meta-analyses to detect an association between the FTO variant
rs8044769 and OA is sufﬁcient (>90%) for the knee and hip
strata (table 2) but ranges from 0.34 to 0.80 for the hip and knee
BMI-stratiﬁed analyses (table 3).
We further investigated the direction of causation between
overweight status and OA using a mendelian randomisation
approach and we computed the summary effect of rs8044769
on overweight status, which results in an OR=1.13[1.07–1.19],
(p=1×10−6), and of overweight status on risk of knee OA and
hip OA (table 2). Overweight status in the current study samples
results in an OR=3.30[3.02–3.62] for knee OA and OR=2.00
[1.82–2.21] for hip OA. We then estimated the expected effect
of the G allele on risk of knee OA if the effect on OA is due to
the effect of rs8044769 on overweight, which would result in
OR=1.16. This value is higher than the upper CI for the
observed effect (OR=1.08[1.02–1.14]. The observed effect for
hip OA (OR=1.04 [0.98–1.11]) is similar to the expected effect
(OR=1.09) of rs8044769.
DISCUSSION
Variation in the FTO gene is associated with obesity although the
exact mechanism by which FTO functions in obesity has not been
elucidated. A recent study by the arcOGEN Consortium estab-
lished an association of rs8044769 at the BMI-associated gene
FTO and knee and/or hip OA reaching almost genome-wide sig-
niﬁcance in the female stratum. FTO demonstrated expression
within OA joint tissues (cartilage, tendon, ligament, meniscus,
synovium, fat pad and osteophyte) and control fracture neck-of-
femur joint tissues but it is unclear whether its expression is modu-
lated by OA.11 The discovery and replication studies did not match
cases and controls for BMI as the discovery dataset employed
population-based controls lacking BMI information. The authors
investigated whether the association with this variant was attenu-
ated after adjustment for BMI using a subset of arcOGEN cases
and disease-free TwinsUK control data with BMI information and
found a substantial attenuation of the association suggesting that
the FTO gene exerts its effect on OA through obesity. However,
due to limited power, no attempt was performed to stratify these
analyses by either OA site or BMI category.11
Another concomitant report that evaluated the genetic
overlap between OA and BMI using fully overlapping samples
to the arcOGEN GWAS reported the same conclusion for a
variant in the FTO locus, rs12149832, which is 3773 kb away
and strongly correlated with rs8044769 (r2=0.7) and is thus
likely to represent the same signal.23 Since it is not clear which
causal variant(s) underlie the association between BMI and
SNPs in FTO5 and OA and SNPs in FTO11 23 we decided to
Table 3 Meta-analysis summary statistics for the association of allele G at rs8044769 with hip or knee OA across the three BMI strata (normal
BMI<25, overweight/obese: BMI≥25, obese: BMI≥30)
OA site Stratum N cases/controls *F.E. OR (95% CIs) F.E. p value †R.E. OR (95% CIs) R.E. p value ‡q p value §I2 ¶Power
Hip Normal-weight 1201/2315 1.08 (0.96 to 1.19) 0.190 1.03 (0.88 to 1.21) 0.691 0.105 0.45 0.47
Hip Overweight/obese 3154/2652 0.97 (0.88 to 1.06) 0.486 0.97 (0.87 to 1.09) 0.602 0.293 0.19 0.73
Hip Obese 1396/848 1.01 (0.88 to 1.15) 0.939 0.98 (0.73 to 1.31) 0.891 0.007 0.68 0.34
Knee Normal weight 936/2501 1.00 (0.90 to 1.12) 0.961 0.98 (0.83 to 1.15) 0.804 0.086 0.46 0.42
Knee Overweight/obese 4473/2861 1.01 (0.93 to 1.08) 0.888 1.01 (0.93 to 1.08) 0.883 0.412 0.02 0.80
Knee Obese 2381/877 0.97 (0.87 to 1.09) 0.603 0.97 (0.79 to 1.19) 0.777 0.017 0.61 0.40
*F.E. Fixed effects.
†R.E. Random effects.
‡q_p value Cochran’s heterogeneity statistic’s p value.
§I2 Heterogeneity index.
¶Power has been calculated for α=0.05, risk allele frequency=0.5 and effect size=1.1, as estimated in the arcOGEN replication only GWAS.11
Table 2 Meta-analysis summary statistics for the association of allele G at rs8044769 with hip or knee OA
OA site Covariates N cases/controls *F.E. OR (95% CIs) F.E. p value †R.E. OR (95% CIs) R.E. p value ‡q p value §I2 ¶Power
Hip Sex 4355/4967 1.04 (0.98 to 1.11) 0.170 1.04 (0.97 to 1.12) 0.287 0.328 0.13 0.90
Hip Sex, BMI 4355/4967 1.00 (0.94 to 1.08) 0.936 0.98 (0.90 to 1.08) 0.749 0.166 0.36 0.90
Hip Sex, BMI, age 4258/4788 1.00 (0.94 to 1.08) 0.97 1.00 (0.93 to 1.08) 0.929 0.312 0.16 0.89
Knee Sex 5409/5362 1.08 (1.02 to 1.14) 0.009 1.08 (1.00 to 1.16) 0.056 0.138 0.38 0.94
Knee Sex, BMI 5409/5362 0.99 (0.93 to 1.05) 0.666 0.99 (0.93 to 1.05) 0.704 0.338 0.12 0.94
Knee Sex, BMI, age 5228/5183 0.96 (0.90 to 1.03) 0.298 0.97 (0.90 to 1.05) 0.484 0.227 0.26 0.93
*F.E. Fixed effects.
†R.E. Random effects.
‡q_p value Cochran’s heterogeneity statistic’s p value.
§I2 Heterogeneity index.
¶Power has been calculated for α=0.05, risk allele frequency=0.5 and effect size=1.1, as estimated in the arcOGEN replication only GWAS.11
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follow-up the association of the variant that showed the stron-
gest evidence for association with OA in the arcOGEN
GWAS.11
In this study, we have investigated whether rs8044769 is asso-
ciated with hip or knee OA independently of BMI by perform-
ing a large-scale meta-analysis across seven cohorts enabling us
to increase the sample size by 55% knee OA cases, 57% hip OA
cases and 69% of controls over the discovery study. This gave us
sufﬁcient power to perform analyses stratiﬁed by joint, joint and
gender, and by joint and BMI category, unlike the original
report, which examined BMI adjustment in females only. We
ﬁnd no evidence for association between this variant and OA
consistent with what is known about the role of the FTO gene
product, namely, that it is likely to be important to the control
of energy homeostasis. As such, it is difﬁcult to envisage a direct
inﬂuence on the development of a joint pathology like OA
except through its role on body mass.
The data presented here can be interpreted in the context of
mendelian randomisation supporting the causal role of over-
weight on OA. Although the association between BMI and OA
is well known, it could be a comorbidity that accompanies the
disease.14 15 The genetic results shown by our study indicate
that, on the one hand, overweight appears to be indeed causa-
tive of OA as we ﬁnd an association between OA and FTO,
which is fully accounted for by the role of FTO on overweight
and disappears once we adjust for BMI or for BMI stratum.
Furthermore, the observed and expected associations between
FTO and hip OA are very similar. On the other hand, we
observe a larger correlation between overweight on knee OA
than what can be explained merely if overweight is causative of
knee OA suggesting that there may be synergistic effects
between overweight and knee OA due to, for example, lifestyle
factors or lack of mobility. Hence, although overweight may be
a cause of OA, the comorbidity and lack of mobility that results
from knee OA may be resulting in further risk of overweight.
We note some study limitations. First, the statistical power of
the current study to detect association of the FTO SNP and OA
is sufﬁcient in the overweight stratum (73%–80%) but is modest
for the normal weight and obese strata (34%–47%). Thus, we
cannot exclude the possibility that a very modest association
may be present among normal weight individuals, which our
study failed to detect. On the other hand, overweight indivi-
duals constitute the majority of OA cases and represent over
70% of the total joint replacement cases.2 The fact that our
study ﬁnds no evidence of association with FTO in the over-
weight stratum despite being sufﬁciently-powered, suggests no
direct implication of the FTO gene in susceptibility to OA. We
also note that our study has combined both OA cases from
population-based cohorts and severe OA cases from case/control
studies recruited via secondary care (see online supplementary
methods). However, we believe that this does not present a limi-
tation of the current study because in the arcOGEN GWAS the
FTO variant was more strongly associated when all cases (ascer-
tained either by radiography or by total joint replacement) were
included in the analysis.11
In summary, unlike the original report of the FTO association
with OA, which was able to adjust for BMI only on a modest
subset of female cases and controls, the present study gives a
deﬁnitive answer showing that the effect of this variant on OA
is solely due to its effect on BMI. Moreover, having tested the
association in the context of mendelian randomisation, the
results in this report indicate that overweight is on the causal
pathway to OA rather than the inverse, although OA-induced
inactivity may also be having an adverse effect on knee OA.
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